Survival Rate of Nasopharyngeal Carcinoma Patients in Phramongkutklao Hospital During 2009 to 2017
Article Sidebar
Main Article Content
Abstract
Background: The standard treatment of nasopharyngeal carcinoma (NPC) depends on the disease staging. The modalities of treatments are radiation therapy (RT) or concurrent chemoradiotherapy (CCRT). In Thailand, the results of the intensity-modulated radiotherapy (IMRT) were limited. Therefore, this study was conducted to determine the overall survival rate (OS) and the disease free survival (DFS) of the different methods of RT. Materials and Methods: The interested population were patients who were diagnosed as NPC and treated in Phramongkutklao Hospital from 2009 to 2017. The study design was retrospective case-control. Results: One hundred eighty-nine patients were diagnosed as NPC. The 5-Year DFS of NPC was 52.91% (95%CI: 44.20-60.87%) and the 5-year OS was 67.53% (95%CI: 58.69-74.89%). The DFS, as well as the OS, of the patients in the early stage and the locally advanced stage, was significantly different (p = 0.019). Patients in the early stage (n = 26) who were treated by RT were divided into Non-IMRT (n = 16) and IMRT (n = 10) groups. There was a significant difference of the DFS in these two groups (p = 0.046) whereas the OS was comparable (p = 0.089). Patients in the locally advanced stage who were treated by CCRT (n = 103) were divided into Non-IMRT + CCRT (n = 60) and IMRT + CCRT (n = 43) groups. Compared to the IMRT + CCRT group, the Non-IMRT + CCRT group was shown to have a comparable OS (p = 0.861) but with a significantly higher DFS (p = 0.027). Conclusions: Patients with the early-stage NPC represented a significantly higher OS. The results of two RTs in the earlystage patients were similar; however, patients with the locally advanced stage NPC who were treated by IMRT + CCRT displayed a higher DFS.
Article Details
References
2. Lee AW, Foo W, Mang O, Sze WM, Chappell R, Lau WH, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-1999): an encouraging reduction in both incidence and mortality. Int J Cancer. 2003;103:680-5.
3. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Chen CJ, Klitz W, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 2002;94:1780-9.
4. Yu MC, Huang TB, Henderson BE. Diet and nasopharyngeal carcinoma: a case-control study in Guangzhou, China. Int J Cancer. 1989;43:1077-82.
5. Zheng YM, Tuppin P, Hubert A, Jeannel D, Pan YJ, Zeng Y, et al. Environmental and dietary risk factors for nasopharyngeal carcinoma: a case-control study in Zangwu County, Guangxi, China. Br J Cancer. 1994;69:508-14.
6. Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol. 1995;69:4390-8.
7. Paine E, Scheinman RI, Baldwin AS, Jr. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NFkappa B/Rel family proteins. J Virol. 1995;69:4572-6.
8. Tangjaturonrasme N, Vatanasapt P, Bychkov A. Epidemiology of head and neck cancer in Thailand. Asia-Pac J Clin Oncol. 2018;14:16-22.
9. Chan JKC, Bray F, McCarron P, et al. Nasopharyngeal carcinoma. In: Barnes L, Eveson JW, Reichart P, et al, eds. WHO classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press, 2005:85-97.
10. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Head and Neck Cancers Version 1.2018 – February 15, 2018, Available from https://www.nccn.org/professionals/physician_ gls/f_guidelines.asp#site
11. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310-7.
12. Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012;13:172-80.
13. Chitapanarux I, Nobnop W, Sripan P, Chumachote A, Tharavichitkul E, Chakrabandhu S, et al. The outcome of the first 100 nasopharyngeal cancer patients in Thailand treated by helical tomotherapy. Radiol Oncol. 2017;51:351-6.
14. AJCC cancer staging manual. 7th edition. Philadelphia: Lippincott- Raven; 2009.
15. Loh KS, Petersson F. Non-exophytic nasopharyngeal carcinoma: high frequency of advanced lymph node and distant metastasis. Otolaryngol Head Neck Surg. 2011;145:594-8.
16. Tuan JK, Ha TC, Ong WS, Siow TR, Tham IW, Yap SP, et al. Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma. Radiother Oncol. 2012;104:305-11.
17. Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, et al. Evolution of treatment for nasopharyngeal cancer-success and setback in the intensitymodulated radiotherapy era. Radiother Oncol. 2014;110:377-84.
18. Chan JY, Chow VL, Wong ST, Wei WI. Surgical salvage for recurrent retropharyngeal lymph node metastasis in nasopharyngeal carcinoma. Head Neck. 2013;35:1726-31.